The Antibody Sector
Arana has a suite of technologies that enables it to create and improve protein based therapeutics such as antibodies. These technologies include its Superhumanisation™, Synhumanisation® and EvoGene™ proprietary processes. A key objective is to generate highly potent therapeutic molecules with reduced immunogenicity.
Arana uses its technologies to decrease development timelines and enhance product profiles for clinical use; with a view to enhancing the welfare of patients and thus the success of the product and creating returns for the company’s shareholders.
An issue with the use of antibodies and other therapeutic proteins is the risk of being recognised as "foreign" material when injected into the body thus provoking an immune reaction ("immunogenicity"). Immunogenicity in the patient can result in a loss of effectiveness of the therapy or unwanted side effects. Arana’s technologies are well suited to addressing these issues as well as enhancing the potency of the molecule.
Arana not only generates its own novel antibodies and protein therapeutic drugs but also uses its technologies to further enhance drugs directed against well-proven disease targets that would
otherwise be blocked from development by patents held by competitors. This helps to reduce the risks associated with the development of Arana’s products.
Arana’s product pipeline targets both inflammatory disease and cancer – both of which are multi-billion dollar markets. Arana’s anti-inflammatory portfolio includes products being developed for rheumatoid arthritis, psoriasis and age-related macular degeneration (AMD). Arana’s development products also target a broad range of common cancers including lung and colorectal cancers, melanoma, other solid tumours and leukaemia as well as cancer spreading to the bone. |
